Skip to content
value.today

Immunophotonics, Inc.

🇺🇸 St. Louis, Missouri, USAPharmaceuticalsFounded 2012
Total raised
$16 M
3 rounds on record
Latest round
$10 M
Jul 2025
First round on record
Jun 2014
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Immunophotonics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2025$10 MNo. 3$10 to $50 million

Immunophotonics, Inc.: Raise no. 3, Jul 2025

Investors in this round

45 investors had bought by the notice of Sep 4, 2026: 41 accredited, 4 not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M (amount offered: indefinite)
Smallest investment taken
$100,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alexander Michael Hurst · Executive Officer
  • Robert H. Arch · Executive Officer
  • Jacqueline M. Hess · Director
  • Jonathan M. Knowles · Director
  • Luciano M. Alleruzzo · Director, Promoter
  • Miguel M. Zubizarreta · Director
  • Richard M. Levenson · Director
  • Wei M. Chen · Director, Promoter

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Raised using rolling closings with majority in a tranche that closed in late August 2026.”
  • On the use of proceeds: “A portion of the gross proceeds will be used for general working capital, a portion of which will include normal salary payments to executive officers. An estimate of such amount is unknown at this time.”

Signed by Alexander Hurst, Chief Corporate Officer, General Counsel, & Corp. Secretary. Source: SEC Form D, newest notice filed Sep 4, 2026. Read the notice at the SEC.

equitySEC
Jan 2023$3 MNo. 2$2 to $10 million

Immunophotonics, Inc.: Raise no. 2, Jan 2023

Investors in this round

22 investors had bought by the notice of Feb 14, 2023: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $7 M offered; $3 M still to sell
Smallest investment taken
$50,000
What was sold
equity
Exemption claimed
  • Rule 504: up to $10 million in twelve months
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Luciano Alleruzzo · Executive Officer, Director, Promoter · CEO, Director, and co-founder
  • Tomas Hode · Executive Officer, Director, Promoter · Chief Innovation Officer, Director, and co-founder
  • Bobby W. Sandage · Director · Chairman of the Board
  • Charlie R. Bolten · Director
  • Jonathan R. Knowles · Director
  • Miguel R. Zubizarreta · Director
  • Wei R. Chen · Director, Promoter · Board member and co-founder

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On fees: “None.”
  • On the amounts: “Rolling closings ongoing as of date of filing.”
  • On the use of proceeds: “A portion of the gross proceeds will be used for general working capital, which may include salary payments to executive officers. An estimate of such amount is unknown at this time.”

Signed by Alexander Hurst, Corporate Secretary, General Counsel, and VP of Operations. Source: SEC Form D, newest notice filed Feb 14, 2023. Read the notice at the SEC.

equitySEC
Jun 2014$2 MNo. 1$2 to $10 million

Immunophotonics, Inc.: Raise no. 1, Jun 2014

Investors in this round

28 investors had bought by the notice of Jan 21, 2015: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $3 M offered; $1 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
  • Section 4(a)(5): accredited investors only, up to $5 million, no public advertising
Meant to last
a year or less
Issuer's revenue
Up to $1 million
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Wyoming

People named in the notice

  • Lu Alleruzzo · Executive Officer
  • Tomas Hode · Executive Officer, Director
  • Bobby E. Sandage · Director
  • Charlie E. Bolten · Director
  • David R. Smoller · Director
  • Peter A. Jenkins · Director
  • Robert E. Nordquist · Director
  • Wei R. Chen · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “The proceeds of the offering may be used for approved executive officer salaries.”

Signed by Tomas Hode, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 21, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Immunophotonics, Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2026).

    SEC Form D · Sep 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Sep 2026

That is all the official record says: Immunophotonics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Immunophotonics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 45 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Immunophotonics, Inc.
NameRoleNamed in
Alexander Michael HurstExecutive officerSep 2026
Robert H. ArchExecutive officerSep 2026
Luciano AlleruzzoCEO, Director, and co-founderFeb 2023
Tomas HodeChief Innovation Officer, Director, and co-founderFeb 2023
Lu AlleruzzoExecutive officerJan 2015
Jacqueline M. HessDirectorSep 2026
Jonathan M. KnowlesDirectorSep 2026
Luciano M. AlleruzzoDirectorSep 2026
Miguel M. ZubizarretaDirectorSep 2026
Richard M. LevensonDirectorSep 2026
Wei M. ChenDirectorSep 2026
Bobby W. SandageChairman of the BoardFeb 2023
Charlie R. BoltenDirectorFeb 2023
Jonathan R. KnowlesDirectorFeb 2023
Luciano AlleruzzoCEO, Director, and co-founderFeb 2023
Miguel R. ZubizarretaDirectorFeb 2023
Tomas HodeChief Innovation Officer, Director, and co-founderFeb 2023
Wei R. ChenBoard member and co-founderFeb 2023
Bobby E. SandageDirectorJan 2015
Charlie E. BoltenDirectorJan 2015
David R. SmollerDirectorJan 2015
Peter A. JenkinsDirectorJan 2015
Robert E. NordquistDirectorJan 2015
Luciano M. AlleruzzoPromoterSep 2026
Wei M. ChenPromoterSep 2026
Luciano AlleruzzoCEO, Director, and co-founderFeb 2023
Tomas HodeChief Innovation Officer, Director, and co-founderFeb 2023
Wei R. ChenBoard member and co-founderFeb 2023